Rhythm Pharmaceuticals Inc To Discuss Hypothalamic Obesity Call Transcript
Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call on hypothalamic obesity. (Operator Instructions)
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Dave Connolly, Executive Director of Investor Relations and Corporate Communications. Please go ahead.
Thank you, Andrea, and thank you all for joining us this morning. For those of you participating via the conference call, there are accompanying slides that can be accessed and controlled by going to the events section on our Investors page at our website, ir.rhythmtx.com. This morning, we issued a press release with our Phase II data from a trial evaluated setmelanotide in hypothalamic obesity as well as the design for our Phase III trial. The press release, which is now available on our website.
Here on Slide 3, I'll remind you that this call contains remarks on future expectations, plans and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |